Breaking News
Get 40% Off 0
🔎 See NVDA's full ProTips for an instant risks or rewards Claim 40% OFF

EU considers retracting Blenrep's authorisation after GSK trial

Published Nov 27, 2023 09:30
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters.
 
GSK
-1.00%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

GSK's Blenrep, a treatment for multiple myeloma, has shown improved progression-free survival rates in a phase III trial, according to the latest results released today. The UK-based pharmaceutical company reported a significant trend toward overall survival among patients with relapsed myeloma. In light of these findings, GSK is expanding the study to gather more robust evidence of Blenrep's efficacy.

Despite these positive results, Blenrep faces regulatory challenges in Europe. Today, the EU proposed withdrawing the drug's conditional marketing authorisation, which could affect GSK's third-quarter revenue of £10 million. This proposition follows earlier setbacks, including advice from the FDA that led to Blenrep's discontinuation in the US market.

The recent trial success comes as a contrast to previous issues Blenrep encountered. Last November, the drug failed to outperform an alternative therapy in a late-stage study. Nonetheless, when used in combination with other treatments, Blenrep has proven effective for patients with relapsed or refractory multiple myeloma.

GSK's disclosure of the successful pivotal trial positions Blenrep as a potential second-line therapy for myeloma, achieving its primary goal of halting disease progression. As GSK continues to investigate Blenrep's long-term benefits, regulatory bodies will likely weigh these new findings against past performance issues before making final decisions on the drug's market availability.

InvestingPro Insights

In the wake of GSK's latest clinical trial results for Blenrep, investors and analysts are closely monitoring the pharmaceutical giant's financial health and market performance. According to real-time data from InvestingPro, GSK boasts a solid market capitalization of $72.89 billion and an attractive P/E ratio of 9.5, indicating a potentially undervalued stock relative to its earnings. The company's revenue growth over the last twelve months as of Q3 2023 stands at 2.16%, reflecting a steady upward trajectory despite the challenges faced.

Two InvestingPro Tips that are particularly pertinent to GSK at this juncture include the company's high return on assets, which stands at 10.78%, and the fact that analysts have revised their earnings upwards for the upcoming period. These insights suggest that GSK is efficiently managing its assets and that there is optimism about its future earnings potential.

For investors seeking more in-depth analysis, there are additional tips available on InvestingPro. Notably, GSK has maintained dividend payments for 23 consecutive years, and with a current dividend yield of 3.71%, it remains an attractive option for income-seeking shareholders.

It's worth noting that the InvestingPro subscription, which includes these and other valuable tips, is now on a special Cyber Monday sale with a discount of up to 55%. For those interested in exploring all 12 tips provided for GSK, visiting the dedicated page on InvestingPro could offer further strategic insights into the company's performance and potential investment opportunities.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

EU considers retracting Blenrep's authorisation after GSK trial
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email